Download Meeting Booklet - International Consortium on Anti

ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
-1-
We gratefully acknowledge the support of our sponsors
CONTENTS
WELCOME ..................................................................
4
CONGRESS INFORMATION ......................................
5
GENERAL INFORMATION ..........................................
6
AGENDA ......................................................................
8
.............................................
8
SATURDAY, OCTOBER 3
-2-
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
SUNDAY, OCTOBER 4
...............................................
10
MONDAY, OCTOBER 5
..............................................
11
TUESDAY, OCTOBER 6
.............................................
12
SPEAKER BIOGRAPHIES .........................................
14
NOTEPAD ..................................................................
23
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
-3-
WELCOME
On behalf of the Organizing Committee we are delighted to welcome you to Corsica for the ICAV/
CITAV 8th International Symposium. The symposium will assemble leading scientists, public health
experts, industry representatives, and philanthropic organizations to advance the development
of safe, affordable and effective anti-viral therapeutics for infectious diseases.
CONGRESS INFORMATION
Key Objectives
Key objectives of the symposium are:
Identify novel therapeutic avenues in the HIV field
Integrate all aspects related to Dengue research in order to organise and impact the nascent
field of emerging virus control strategies
Identify and bridge the gaps in the rapidly evolving field of emerging viruses
Focus on the global public health response to H1N1
Identify and develop innovating funding and spending mechanisms where public attention is
competing with the worldwide financial crisis.
Meals and accommodations incurred in connection with attending the Symposium will be
covered for approved registrants. Unfortunately we are unable to cover travel costs to and from
this meeting.
Accommodation will be at the Hotel Coralia Club Porticcio Marina Viva. The symposium will take
place at the Palais des Congrès et des Expositions d’Ajaccio in Ajaccio, Corsica.
Transfers
Transfers from Hotel to Convention Centre and back by boat, please check
the practical information memo sent out before the congress for departure
times.
Posters
Poster set-up will take place Saturday afternoon. Official time for viewing
is scheduled Sunday October 4 afternoon. Please ensure that you remove
your poster before 4 pm on Monday October 5.
Organizing Committee
Bruno Canard Jeremy Carver Lorin Charlton Michel Chrétien
Rolf Hilgenfeld Christine Hodge Rajan Shah Contact
Contact
Agency ATouT.Com
Aix en Provence - France
www.atoutcom.com
Cell phone contact: Anette
+33 (0)6 27 40 39 77
Elysabeth +33 (0)6 68 69 85 40
-4-
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
-5-
GENERAL INFORMATION
Ferry Information
ICAV will cover the ferry cost from Marseille to Ajaccio and back.
Name of boat: Napoléon Bonaparte
2nd October Marseille - Ajaccio (Corsica):
Departure: 8 pm (the group needs to be there 1h30 in advance)
Arrival 7 am on October 3rd
6th October Ajaccio - Marseille:
Location
Ajaccio where the Convention Centre (« Palais de Congrès » in French) is located, lies
on the West coast of the island of Corsica in a sheltered position at the foot of wooded
hills on the Northern shore of the Gulf of Ajaccio. The harbour lies to the east of the
town and is protected in the South by a peninsula. Napoleon Bonaparte was borne
there in 1769. His memory is firmly entrenched in the city and is further embellished
by the many gifts his family, descendants and admirers donated to the city.
The Conference Hotel, Coralia Club Marina Viva, is located in the heart of the seaside
resort of Porticcio, 17 km from the Convention Centre. This hotel by the sea amidst
trees and flower-filled gardens looks out on the Gulf of Ajaccio and the Sanguinaire
Islands.
Departure : 8 pm (the group needs to be there 1h30 in advance)
Arrival 7.30 am on October 7th
Details:
Accommodation in outside single (double for participants with guest)
cabins (with window) with bathroom.
Welcome cocktail on upper level of Bar « Le Galaxie » (deck 11).
Dinner and breakfast in private dining room « Le Sillage d’Argent » (deck 9).
Pratical Information
Currency:
1 Euro = 100 centimes (= 1,58 CAD on 09/29/09)
Telephone:
The international code is 00 + country code
The international access code for France is +33
Electricity:
Electrical current is 220 volts, 50 Hz. European two-pin plugs are standard.
Don’t forget your adaptors and converters.
ATM machines:
There is no ATM teller inside the Hotel Club, but there are banks with ATM
tellers nearby (Crédit Agricole)
-6-
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
-7-
AGENDA
October 3-6, 2009
Leave on overnight ferry from Marseille to Ajaccio on the evening of Oct 2nd. On board you are
invited to attend the welcome cocktail reception on the upstairs level of the bar “Le Galaxie” at
7.30 pm. The reception is being sponsored by Arrow Therapeutics/Astra Zeneca. Dinner will
follow at 8:30 pm. We will arrive in Corsica at ~ 7 am Oct 3rd.
Session 2: HIV - Present and Future Challenges
Focus: What’s next in the HIV field regarding novel therapeutic avenues, vaccine design,
community-based awareness, and innovative funding and incentives in a global context where
public attention is competed by the worldwide financial crisis as well as novel pandemic
threats?
Chair: Bruno Canard
1:00-1:45 pm
Anne-Sophie Beignon (Pasteur Institute, France)
“AIDS vaccine: where are we now?”
All sessions in Ajaccio Oct 3-6
1:45-2:30 pm
Jan ter Meulen (Merck, USA)
The format will be several presentations on each topic followed by a panel. Each panelist will be
asked to make a brief presentation; the panel will then be opened for questions from the floor.
2:30-3:00 pm
Jörg Hofmann (Charité Campus Benjamin Franklin, Germany)
3:00-3:30 pm
COFFEE BREAK
3:30-4:00 pm
Evelyne Jacqz-Aigrain (hospital Robert Debre, France)
4:00-4:30 pm
R.S. Paranjape (NARI, India)
4:30-5:00 pm
Bruno Spire (INSERM, France)
5:00-5:30 pm
Panelists:
Saturday, October 3
Session 1: Go viral: Innovative financing - Innovative spending
Focus: The UNITAID funding model is evolving. This innovative funding model will be presented
by Dr. Philippe Douste-Blazy, UN Under-Secretary for Innovative Financing. The research and
drug & diagnostic development communities need to develop an « innovative spending » model
that meets the expectations of these emerging innovative funding mechanisms. ICAV will present
a « straw-man » proposal for discussion and elaboration.
Chair: Michel Chrétien (OHRI, Canada)
10:00-10:45 am Philippe Douste-Blazy (UNITAID, France)
10:45-11:30 am Jeremy Carver (ICAV, Canada)
« Suggestions for Innovative Spending »
12:00-1:00 pm LUNCH
-8-
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
« Long-term control of HIV by allogeneic CCR5-U32/U32 stem
cell transplantation »
« How to increase availability of drugs for children :
scientific and regulatory aspects »
« Virology of Indian HIV epidemic and initiatives for anti-HIV drug
development »
« Perceptions and behaviors of people living with HIV/AIDS :
the interest of a multidisciplinary approach »
Anna Vyakarnam (King’s College, UK)
James Brandful (Noguchi Memorial Inst. of Medical Research, Ghana)
Jonathan Stoye (Mill Hill, UK)
Dana Wolf (Hadassah University Hospital, Israel)
11:30-12:00 pm Panelists & Discussion:
R.S. Paranjape (NARI, India)
Oyekanmi Nashiru (ICAV, Nigeria)
Sunday Omilabu (University of Lagos, Lagos)
« Current challenges to the development of HIV vaccines and antivirals »
5:30-6:00 pm
Discussion
7:00-9:00 pm
COCKTAILS AND DINNER
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
-9-
Sunday, October 4
Monday, October 5
Session 3: Dengue - An integrated model
Sessions 4 & 5: Emerging Viruses
for arthropod-borne viral disease control
Focus: Dengue is a robustly emerging disease transmitted by mosquitoes of the Aedes species
in tropical and subtropical areas of the world. The global disease burden and control challenge
has made of Dengue a model for other arthropod-borne diseases in terms of science, prevention,
vector control, community-based measures, societal and economic impact. The goal of this
session is to integrate all aspects related to dengue research in order to organize and impact the
nascent field of emerging virus control strategies.
Chair: Olaf Horstick (WHO, Switzerland)
8:30-9:15 am
Eva Harris (UC-Berkley, USA)
« Dengue: From the bench to the field and back »
9:15-10:00 am Xavier de Lamballerie (Universite Aix Marseille 2, France)
« Arbovirus evolution and quasispecies: arguments for implementing
antiviral treatments »
10:00-10:30 am COFFEE BREAK
10:30-11:00 am Jerome Deval (Roche, Palo Alto, USA)
« Inhibiting the polymerase of Dengue Virus: a Company perspective »
11:00-11:30 am Julien Lescar (Nanyang Technological University, Singapore)
« Structural views of the NS3 and NS5 proteins from flaviviruses »
11:30-12:00 pm Robert S. Fuller (USA)
« A novel family of pharmacologically-validated, non-competitive inhibitors
of furin as potential broad spectrum anti-virals and anti-microbials »
12:00-12:30 pm Panelists:
Bruno Canard (CNRS, France)
Cecilia Dayaraj (NIV, India)
Subhash Vasudevan (Duke-NUS Graduate Medical School, USA)
Paul Young (University of Queensland, Australia)
Wendy Hill (ICAV, Canada)
12:30-1:00 pm Discussion
1:00-2:00 pm
LUNCH
Formal Poster Presentation Session
2:00-5:00 pm
Poster Session
2:30-3:30 pm
MOU Signing (by invitation only)
3:30-4:30 pm
International Steering Committee Meeting (by invitation only)
7:00-9:00 pm
COCKTAILS AND DINNER
- 10 -
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
Focus: Emerging viruses impose a large number of totally novel constraints on society. Not only
is scientific knowledge lacking regarding rapid implementation of control measures (eg. antivirals,
vaccines), but challenges associated with vector control, community reaction and education, as
well as funding schemes to develop efficient protective measures are totally undeveloped.
The current preparedness and response plans developed by public health agencies have not
involved or engaged classical stakeholders, such as companies and academics, in a landscape
where most response schemes (eg. classical grant-funded research, massive and rapid
diagnostics, clinical trials, patient care…) are not suitable to face a crisis situation and need
significant input from these sectors. This session will work on the identification and bridging of
the numerous gaps in this rapidly evolving field.
The rapid emergence and spread of H1N1 with gene segments from swine, avian and human
origin demonstrates the need for continued surveillance of all known reservoirs for influenza and
the refinement of predictive methods for human-to-human transmission and virulence. Session
4 will focus on the global public health responses to the H1N1 pandemic and how they could be
improved.
A non-academic view
Chair: Nabil Seidah (IRCM, Canada)
8:30-9:15 am
Ernest Gould (Oxford University, Oxford)
« Emerging Viruses: Humans are man’s worst enemy! »
9:15-10:00 am Pilar Najarro (Arrow, UK )
« Industry’s challenges in antiviral drug discovery:
a not-so-small company point of view »
10:00-10:30 am COFFEE BREAK
10:30-11:00 am Noël Tordo (Institut Pasteur, France)
« Antiviral strategies against negative strand RNA viruses »
11:00-11:30 am Panelists:
Rolf Hilgenfeld (University of Lübeck, Germany)
Guenter Kraus (Tibotec, Belgium)
Brahm Srivastava (CDRI, India)
11:30-12:00 pm Discussion
12:00-1:30 pm LUNCH
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
- 11 -
Focus on significant candidates
Chair: Ernest Gould (University of Oxford, UK)
1:30-2:15 pm
Angela McLean (Oxford, UK)
2:15-3:00 pm
Guy Boivin (Québec City University Hospital Center, Canada)
3:00-3:30 pm
COFFEE BREAK
3:30-4:00 pm
Bruno Canard (Laboratoire AFMB, France)
« Modeling Pandemics »
« Influenza resistance to neuraminidase inhibitors”
4:00-4:30 pm
« Broad spectrum preparedness against emerging viruses:
Achievements of the VIZIER project. What’s next? »
Ernest Gould (University of Oxford, UK) « EVA - European Virus Archive »
4:30-5:00 pm
Panelists:
Johan Neyts (University of Leuven, Belgium)
Dale Cumming (ICAV, Canada)
Junli Liu (China CDC/IST, China)
Dana Wolf (Hadassah University Hospital, Israel)
Yossef Av-Gay (University of British Columbia, Canada)
Eleanor Fish (UHN, Canada)
5:00-6:00 pm
Discussion
7:00-9:00 pm
COCKTAILS AND GALA DINNER - Pierre Jeanniot (FAV, Canada)
9:00 pm
Closing Comments
- Michel Chrétien (OHRI, Canada)
Tuesday, October 6
Sessions 6: Late Breaking News
Chair: TBA
9:00 am-12:00 pm Rolf Hilgenfeld
Eleanor Fish
- 12 -
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
- 13 -
SPEAKER BIOGRAPHIES
Bruno Canard
Yossef Av-Gay
Professor at the Division of Infectious
Diseases Department of Medicine at
the University of British Columbia,
Vancouver, Canada. He is a microbiologist engaged in preclinical studies of
respiratory pathogens leading to antimicrobial and
antiviral drug development. His research focuses
on basic scientific understanding of Mycobacterium
tuberculosis and Influenza physiology within the
human host. His and Dr. Chris Miller’s application
for the use of gaseous nitric oxide as a broad range
drug for pandemics was recently approved by Health
Canada for safety studies in human volunteers. Prof.
Av-Gay has authored more then 50 peer-reviewed
scientific publications, review articles, book chapters
and holds 10 patents. He serves on scientific advisory
boards and is a consultant to several biotechnology
companies. Prof. Av-Gay is also a member of the
scientific review panels of the Canadian Institute of
Health Research and the European Commission.
Anne-Sophie Beignon
She obtained her PhD degree at the
University of Strasbourg in 2002 after
spending three years in the laboratory
of Dr S. Muller working with Dr C.D.
Partidos on skin immunization. Skin
had been described as an impermeable barrier for the
penetration of large molecules and, back in 1999, it
was re-emerging as a potent route for non-invasive
delivery of vaccines. Dr. Beignon then joined the laboratory of Dr N. Bhardwaj in NYC in 2002 as a postdoctoral fellow where she characterized the immunostimulatory capacities of R-848, a cheap synthetic
molecule designed in the early eighties and back on
stage because of the identification of its receptor, i.e.
TLR7 and 8, and its potential use as transcutaneous
adjuvant. She has also worked on the biology of plasmacytoid dendritic cells, which express TLR7 and 9
and found that HIV activates them via TLR-viral RNA
interactions. Dr. Beignon now continues her research
at the Institut Pasteur with Dr P. Charneau using
lentiviral vectors derived from HIV as vaccine vector
against HIV infection itself.
Guy Boivin
He’s a medical microbiologist/virologist
and an infectious disease specialist
working at the Québec City University
Hospital Center (CHUQ-CHUL) in
Canada. Dr. Boivin is also a professor
of medical biology (division of microbiology) at Laval
- 14 -
University and a senior researcher in virology at the
Research Center in Infectious Diseases of the same
University. Dr. Boivin holds a MD from Laval University, an MSc degree in microbiology from University
of Montréal and 3-year specialized research training
(Fellowship) in Molecular Virology from University of
Minnesota. Dr. Boivin is currently the holder of the
Canada research chair on Emerging Viruses and Antiviral Resistance (2006-13). He is also the director of
the Canadian Center of Excellence on Herpesviruses
and he holds numerous research grants from governmental health organizations (Canadian Institutes of
Health Research, Quebec Health Research Foundation) and private companies. His main research interests concern the diagnosis, pathogenesis and treatment of viral diseases caused by herpesviruses (mainly
cytomegalovirus and herpes simplex virus) and respiratory viruses (mainly influenza virus, human metapneumovirus and human respiratory syncytial virus)
and the mechanisms of resistance to antiviral drugs.
Dr. Boivin is a member of several distinguished societies including the American Society for Microbiology,
the American Society of Transplantation, the Canadian
Association of Medical Microbiology and Infectious
Diseases, the Canadian Society for Clinical Investigation and the Quebec AIDS and Respiratory Diseases
Networks. In addition, Dr. Boivin has published more
than 150 peer-reviewed manuscripts and presented
more than 200 communication abstracts since 1993.
He is on the Editorial board of the Journal of Infectious
Diseases, Herpes Journal and the Canadian Journal
of Infectious Diseases.
James Brandful
Molecular virologist and Head of the
Department of Virology of Noguchi
Memorial Institute for Medical Research
(NMIMR), University of Ghana, one of
Ghana’s most prestigious biomedical
research institutes. His work since the late 80s has
focused mainly on enteroviruses, namely Coxsackie
A24 variant and EV70 responsible for a highly infectious but limiting haemorrhagic eye condition which
broke out extensively in Ghana in the 70s and 80s. He
has also worked extensively on the molecular epidemiology and phenotypic characterization of HIV in
Ghana and implications for antiretroviral therapy, HPV
and cervical cancer in Ghanaian women and some
serum biomarkers associated with HIV/AIDS progression. He has an interest in viral haemorrhagic and
emerging diseases and the development of antivirals
against such conditions.
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
Xavier de Lamballerie
Director of Research in the French
research agency CNRS, and is the
AFMB deputy director. He got his PhD
in the Pasteur Institute under the supevision of Dr S.T. Cole in 1991. He was
recruited to a permanent position in the CNRS in 1992.
He took a post-doctoral position at Harvard Medical
School from 1995 to 1998 in the laboratory of Pr.
Charles C. Richardson, where he started his research
on HIV RT-mediated drug resistance, which later led
to his focus on viral replicases. He got an ATIPE starting grant in Marseille in 1998 in the AFMB laboratory
headed at that time by Dr. Christian Cambillau. In
2004, both Christan Cambillau and Bruno Canrd launched the VIZIER project, a structural genomics project
addressing RNA virus replicases. Bruno Canard took
the coordination of VIZIER in July 2005. VIZIER contributed to 85 structures of viral enzymes (AFMB was
involved in more than 45 of them). VIZIER exemplifies
how shared resources and a strong project culture can
boost research in virology and antiviral research. The
project has been elected as an EU-FP6 success story.
Dr. Canard is presently in charge of the AFMB group
«Viral replication: structure, mechanism, and drugdesign» in the AFMB Structural Virology department.
The Structural Virology department counts 25 to 30
people, and has set up an open platform for protein
production, protein 3D determination and replicase
assays. The AFMB has also hosted EMBO practical
courses in 2005 and training activities relevant to
ongoing projects. Bruno Canard has published 115
articles in refereed journals and has deposited >26
structures in the PDB (September 2009). He has been
awarded the William Prusoff prize for antiviral research
in 2008.
Jeremy P. Carver
Co-founder and CEO of ICAV. He is
also Chair of the Advisory Committee
of the NRC Institute for Biological
Sciences and is a Director of Translational Medicines, a Boston biotechnology company. Dr. Carver is an Emeritus Professor of
the University of Toronto and an Honorary Conjunct
Professor at Trent University. Dr. Carver chaired the
Board of the Protein Engineering Network of Centres
of Excellence (PENCE) from 2002 until 2006. From
1994 to 2002 he was the Founding President, CEO
and CSO of GlycoDesign Inc. He was a Professor
and Associate Dean in the Faculty of Medicine at
the University of Toronto (1968 - 1994), a Helen Hay
Whitney Postdoctoral Fellow at Oxford University
(1966-68) and a World Trade Visiting Scientist at IBM
Watson Labs, New York (1977).
He has a degree in Chemistry and a
Doctorate in Medicine from the Univesity of Marseilles, where in 1995 he also
obtained his PhD. He is currently
Professor of Microbiology at Marseille
Medical University’s Emerging Viruses Unit, where
he is responsible for overseeing the Virology Department research programme. Dr. de Lamballerie is
also in charge of the Virology Unit of the Microbiology Department at La Timone Hospital, Marseille. In
1996 Dr. de Lamballerie was the first to demonstrate
the nosocomial transmission of the Hepatitis C virus in
haemodialysis units using phylogenetic tools. During
the same year he established the first research laboratory dealing with clinical virology in collaboration with
Professor Ph. De Micco. This unit is specialised in
diagnosis, genomics and genetics of RNA viruses and
established the complete sequences of more than 40
RNA viruses including flaviviruses, arenaviruses and
reoviruses. In 1997 he was the first to conduct epidemiological and molecular studies in Europe on the
GB virus-C and on the TT virus, and in 1998 he established the first genomic sequences and taxonomic
classification of Coltiviruses and a new genus - the
Seadornavirus genus - within the Reoviridae family.
Regarding avian/human influenza, Dr. de Lamballerie is the coordinator of Section 2 (Virus Production
and Genome Sequencing) of the EU-funded VIZIER
programme. This programme aims to have a groundbreaking impact on the identification of potential
new drug targets against RNA viruses by providing a
comprehensive structural characterization of the replicative machinery of a carefully selected and diverse
set of viruses.
Dr. de Lamballerie is thrilled to be part of VIZIER,
which he describes as unique because it gathers
experts from a vast range of scientific disciplines and
gets them working together in a major structural effort,
within a broad multidisciplinary study that has virology
upstream and target validation downstream. To date,
more than 350 species of viruses that possess an RNA
genome and can infect vertebrates have been identified, but only 30% have been sequenced. VIZIER has
developed a strategy for the rapid characterization
of the missing genomes; work which Dr. de Lamballerie endorses with great enthusiasm. Moreover, he is
particularly appreciative of the efforts that the EU has
taken to get this complex project up and running. He
is confident that it will have an extremely beneficial
effect on society.
VIZIER: Comparative structural genomics on viral
enzymes involved in replication
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
- 15 -
Jerome Deval
Graduated in 2000 from the engineering school of ESIL in France, with a
major in Biotechnology. Immediately
after, Jerome started a PhD program
in Biochemistry under the supervision of Dr. Canard at the French CNRS in Marseille.
During that time, Jerome studied mechanisms of
resistance of HIV reverse transcriptase to nucleoside
analogues. After he graduated with his PhD in 2004,
Jerome joined the laboratory of Dr. Gotte at McGill
University in Canada, where he established methods
to study the inhibition of the polymerase of hepatitis
C virus in vitro. Jerome is now a research scientist in
the Virology department of Roche in California. He is
the lead biochemist for the dengue virus project, and
also supports other programs such as HCV. Jerome is
married and has two children.
Eleanor Fish
She’s the Canada research chair in
Women’s Health & Immunobiology, a
McLaughlin Scholar and was elected
as a Fellow to the American Academy of
Microbiologists. Dr. Fish received her
undergraduate degree at the University of Manchester,
England, and her Master of Philosophy in Virology at
the University of London, England. She completed her
PhD in Cell Biology at the Institute of Medical Science
at the University of Toronto, Canada. Dr. Fish is a
member of several societies, including the American
Society for Biochemistry and Molecular Biology, the
Canadian Society for Immunology, the International
Cytokine Society, and the International Society for
Interferon and Cytokine Research, for which she is
President. She is on the editorial board for the Journal
of Interferon and Cytokine Research. Her work has
been published in many scientific journals, such as
the Journal of Immunology, Experimental Hematology, Circulation, Blood, Nature, PNAS, JAMA and
the Journal of Biological Chemistry. Dr. Fish studies
the interactions of cytokines, specifically interferons and chemokines, with their receptors in normal
and diseased tissues and cells. A focus of Dr. Fish’s
research is associated with autoimmune diseases,
specifically rheumatoid arthritis, multiple sclerosis and
lupus. Dr. Fish’s research involves biomarker discovery to develop intervention therapeutics for patients
with RA. Another major focus of her work is the investigation of host-pathogen interactions at the cellular
and molecular level, specifically in the context of interferons and chemokine receptors. During the 2003
outbreak of SARS in Toronto, she initiated studies to
investigate the therapeutic potential of interferon in
SARS patients. Encouraging results have directed her
group’s efforts toward examining interferon activity
against a number of emerging infectious diseases,
such as avian flu.
- 16 -
Robert S. Fuller
Professor of Biological Chemistry at
the University of Michigan Medical
School. Dr. Fuller obtained his BS
(1978), in Molecular Biophysics and
Biochemistry at Yale University and his
PhD (1984) in Biochemistry, from Stanford University.
He completed Postdoctoral training from 1984-1987
in Microbiology and Immunology & Biochemistry at
the University of California, Berkeley. From 1987-1994
Dr. Fuller was Assistant Professor, Biochemistry, at
Stanford University. From 1994-1999 he was an Associate Professor, Biological Chemistry at the University
of Michigan; and from 1999-present he is a Professor,
Biological Chemistry at the University of Michigan. Dr.
Foster has received many awards: 1978, magna cum
laude, Yale University; 1978-1984, NIH predoctoral
trainee; 1984-1987, Helen Hay Whitney Postdoctoral
Fellow; 1986-1992, Lucille P. Markey Scholar; 1990
SmithKline Becham Scholar Award; 2000, Faculty
Recognition Award, University of Michigan. His
research has included: PhD research with Professor
Arthur Kornberg: replication of the bacterial chromosome and role of DnaA protein; Postdoctoral, with
Professor Jeremy Thorner: Processing by proprotein
processing protease, Kex2, in yeast; Independent:
Proteolytic processing in the secretory pathway;
biochemistry, structure and function and inhibition of
proprotein processing proteases; protein localization
and processing in the secretory pathway; yeast cell
biology.
Ernest Gould
He started his virology career as a
Postdoctoral fellow at the University
of Birmingham and was then appointed
lecturer at Queen’s University Belfast,
subsequently becoming a senior
lecturer in the London School of Hygiene and Tropical
Medicine. He was then appointed Assistant Director
at the Institute of Virology in Oxford where he focused
his research on Arboviruses. During the past 25 years
he has developed a strong interest in viral pathogenesis, evolution, persistence, and emergence, and
has published nearly 200 papers on these subjects.
In 2003, he retired from his position as Director in
Oxford and is now working as a Visiting Professor
in the Unité des Virus Emergents, Marseille, where
Professor Xavier de Lamballerie is the Head.
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
Eva Harris
Rolf Hilgenfeld
She’s currently a Professor in the Division of Infectious Diseases in the
School of Public Health and Director
of the Center for Global Public Health
at the University of California (UC)
Berkeley. She received a BA in Biochemical Sciences
from Harvard University and a PhD in Molecular
and Cell Biology at UC Berkeley. As a faculty at UC
Berkeley, she has developed a multidisciplinary
approach to study the molecular virology, pathogenesis, and epidemiology of dengue, the most prevalent
mosquito-borne viral disease in humans. One major
research focus has been the development of a mouse
model to study viral tropism and pathogenesis, investigate the immune response to dengue virus infection,
and generate a better model of disease. This has
resulted in a mouse model for antibody-dependent
enhancement of dengue disease that is being used
extensively to test different classes of candidate antiviral compounds that target 1) the virus itself, 2) host
processes essential for dengue virus infection, 3) the
interaction between virus-immune complexes and the
Fc receptor, and 4) vascular leak syndrome. Another
area of research is the mechanism of viral translation and replication, particularly cis-acting elements
in the viral genome. Her field work focuses on laboratory-based and epidemiological studies of dengue
in endemic Latin American countries, particularly in
Nicaragua, where ongoing projects include clinical
and biological studies of severe dengue, a pediatric
cohort study of dengue and influenza transmission in
Managua, and a project on evidence-based, community-derived interventions for prevention of dengue
via control of its mosquito vector. She has also collaborated with investigators in the Department of Electrical Engineering at UC Berkeley to develop novel,
rapid, low-cost diagnostic devices for point-of-care
diagnosis of dengue and other infectious diseases. In
1997, Dr. Harris received a MacArthur “Genius” Award
for her pioneering work over the previous ten years
developing programs and working to build scientific
capacity in developing countries to address public
health and infectious disease issues. To continue and
expand this work, in 1998 she founded a non-profit
organization in San Francisco, Sustainable Sciences
Institute (SSI; www.ssilink.org) and published a book
on the subject with Oxford University Press. She was
co-Director of the Fogarty International Center’s «International Training and Research in Emerging Infectious
Diseases» program at UC Berkeley from 1997-2003.
In 2001, Dr. Harris was named a Pew Scholar for her
work on dengue pathogenesis. In 2002, she received
the Prytanean Faculty Award for outstanding women
faculty as well as a national recognition award from
the Minister of Health of Nicaragua for her contribution
to scientific development, and she was selected as a
“Global Leader for Tomorrow” by the World Economic
Forum. Dr. Harris has published over 90 peer-reviewed
articles, as well as a book on her international scientific work.
He was among the first scientists to
determine the structure of the HIV-1
protease and to design inhibitors
against this target. Since 2003, Dr.
Hilgenfeld has been Full Professor of
Biochemistry at the University of Lübeck, Germany.
His research focuses on the molecular basis of infectious diseases by bacteria such as Legionella pneumophila and Chlamydia and by RNA viruses. During
the global SARS epidemic of 2003, he published the
crystal structure of the coronavirus main proteinase
and proposed a first inhibitor against the disease. His
Lübeck laboratory follows an integrated approach
to drug discovery against infectious agents, which
includes comparative proteomics, molecular biology,
X-ray crystallography, drug design and chemical
synthesis of inhibitors.
Jörg Hofmann
He completed his PhD in organic
chemistry at the Karl-Marx-University
Leipzig. From 1988 – 1995 he held a
Postdoctoral position at the Institute of
Medical Microbiology, Department of
Virology, at the University of Leipzig. From 1995- 2006,
Dr. Hofmann was a Postdoctoral research fellow at the
Institute of Virology at the University of Leipzig. Since
2006 Dr. Hofmann has been head of the diagnostic
department of the Institute of Medical Virology, Charité
University Hospital Berlin.
Evelyne Jacqz-Aigrain
Medical doctor who graduated from
the University René Descartes in Paris,
France. She trained in Paediatrics at
the Hospital Necker-Enfants Malades
during a four year residency and was
associate Professor in Paediatrics and Neonatal Intensive care for two years. She trained as a post doctoral
research fellow in Clinical Pharmacology with Pr C.
Dollery in London UK, and with J. Oates and G. Wilkinson in Nashville, USA, and graduated with a PhD in
Pharmacology. She worked for four years as a researcher at INSERM. She is now head of the Department
of Paediatric Pharmacology and Pharmacogenetics,
hospital Robert Debre, in Paris, France and responsible for the “French Network of Paediatric Clinical
investigation Centers. She is also an active member
of the European Society for Developmental, Perinatal
and Paediatric Pharmacology.
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
- 17 -
Pierre Jean Jeanniot
Chairman of the Foundation on Antivirals and Director General Emeritus of
the International Air Transport Association, a lifetime title awarded in
recognition of his outstanding contribution IATA and to international civil aviation. He
currently acts as advisor to the worldwide THALES
Group, SECOR Consulting and Jet Airways (India),
and Chairs the Boards of a number of IT companies. Pierre Jeanniot was President and CEO of Air
Canada from 1984-1990 and early in his aviation
career he was instrumental in developing the famous
“Black Box”. He has devoted himself to many social
and charitable causes, and was Chancellor of the
Université du Québec à Montréal - UQÀM until 2008,
having previously been Chairman of the Board, and
President of its Foundation. He was also Honorary
President of the Canadian Cancer Society’s fund-raising campaign. Mr. Jeanniot is an Officer of the Order
of Canada, a Chevalier de la Légion d’Honneur in
France, and received the Independence Medal of the
First Order from H.K. King Hussein of Jordan in 1995.
Mr. Jeanniot holds a Doctorat Honoris Causa, from
the Université du Québec, an Honorary Doctorate in
International Law from Concordia University, and an
Honorary Doctorate in Science from McGill University.
He is a Fellow of the Royal Aeronautical Institute and
has been indicted into the Québec Hall of Fame.
Guenter Kraus
Tibotec’s Infectious Disease and RED
Liaison Officer. He is leading the early
development efforts at Tibotec and
responsible for scientific liaison of
Research and ED programs and novel
infectious diseases initiatives. Before taking on this
role he was Sr. Director in the clinical virology department leading the clinical virology laboratory. Dr.
Kraus’s academic credentials span more than 12
years of antiviral research at UCSD and the University
of Miami. Guenter received his training in virology at
the Paul-Ehrlich-Institute.
Julien Lescar
Associate Professor with the School of
Biological Sciences, Nanyang Technological University (NTU), Singapore.
He directs research programs on the
structural biology of neglected infectious diseases caused by RNA viruses and malaria.
He has made contributions to the structural virology of
positive strand RNA-viruses which comprise several
important human pathogens. Having determined the
first 3D structures for flavivirus and alphavirus envelope proteins, and several key viral enzymes including
the helicase, protease and polymerase from dengue
virus, he is one of the leading Dengue structural biologists worldwide. During the last five years, he has been
- 18 -
collaborating with the Novartis Institute for Tropical
Diseases in Singapore and also with the group of Bruno
Canard, CNRS Marseille. He set-up the X-ray crystallographic facility at NTU, which currently comprises one
Rigaku micromax007HF generator and two imaging
plate detectors a facility which is running 24/7 and is
also used by local biotech companies. He is a regular
reviewer for MRC grants (UK), European grants and for
international journals like J. Virol., Virology, Structure,
Plos-Pathogens, Molecular Microbiology, RNA, Virus
Research, Antiviral Research, Biochemical Journal,
Biochemistry, Proteins, Protein Science, Febs Journal
among others. He has published more than 50 peer
reviewed articles that have attracted more than 1000
citations and is the author of one provisional US-patent on a monoclonal antibody that inhibits all four
dengue serotypes.
Angela McLean
She studied mathematics at Oxford
followed by a PhD in biomathematics
at Imperial College, London. After a brief
spell in the City she joined the Mathematical Biology Group at the National
Institute for Medical Research at Mill Hill. Dr. McLean
returned to Oxford as a Royal Society University
Research Fellow in 1990 and took a secondment to the
Institut Pasteur in Paris in 1994. In 1998 she became
Head of Mathematical Biology at the BBSRC’s Institute for Animal Health. Returning to Oxford in 2000, Dr.
McLean became Professor of Mathematical Biology
in 2004. In 2005 she became Director of the Institute
for Emerging Infections – a founding Institute of the
James Martin 21st Century School. Since 1st October
2008 she has been a Senior Research Fellow at All
Souls College.
Pilar Najarro
Head of Virology at Arrow Therapeutics
(a wholly owned subsidiary of Astra
Zeneca) and has contributed to the
development and successful application
of methodology to elucidate the
mode of action and genetic barrier of resistance of
small molecule antivirals. Several of those are now
in clinical development. Prior to joining the pharmaceutical industry four years ago Dr. Najarro’s efforts
were mainly focused on host-pathogen interactions
and viral immune evasion. After completing BSc and
MS studies at the Universidad Autónoma in Madrid,
Dr. Najarro received her PhD in vaccinia-cell interactions at the State University of New York Downstate
Medical Centre in Brooklyn, followed by a post-doctoral fellowship at the Wright-Fleming Institute at the
Imperial College in London.
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
Oyekanmi Nash
Director of the African Regional Office
of the International Consortium on AntiVirals (ICAV), is the Deputy-Director
(Collaboration and Linkages) with the
National Biotechnology Development
Agency (NABDA), Federal Ministry of Science and
Technology, Abuja-Nigeria. He is also the Coordinator
of the Initiative for Translational Research on Tropical
and Emerging Infectious Diseases at the NABDASouthwest Biotechnology Centre of Excellence at the
University of Ibadan. He is an Adjunct Lecturer with
the Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan. Before
returning to Nigeria in 2006, he was a Research Associate with the Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York,
where he worked on the evolution of HIV-1 Reverse
Transcriptase for Molecular Biology applications. As a
Post-Doctoral Fellow with the Canadian Protein Engineering Centre of Excellence (PENCE), he had worked
on the engineering of the first «Mannosynthase.» at the
University of British Columbia, Vancouver, Canada. He
is the Program Director of the West African Biotechnology/Bioinformatics Workshops Series (WABWS).
Johan Neyts
Full professor of virology at the University of Leuven. His research is focused
on the development of novel antiviral
strategies against a number of RNA
viruses including picornaviruses, flaviviruses and HCV. He has also a long standing expertise with respect to the development of small animal
models for flavivirus infections and with the molecular virology of flaviviruses. His team discovered the
anti-HCV activity of Debio-025, a compound which is
now in phase II clinical development by DebioPharm
(Lausanne, Switzerland). Together with Prof. Gerhard
Puerstinger (University of Innsbruck, Austria) he also
discovered a novel class of HCV inhibitors, of which the
potent compound GS 9190 is now in phase II clinical
development at Gilead Sciences (Foster City, CA,
USA) and together with Prof. C. Mc Guigan (University
of Cardiff) he discovered a novel prodrug approach
to treat HCV infections (in preclinical development at
Inhibitex, Alpharetta, Georgia).
He is inventor on a number of patents in the antiviral field
of which the majority have been licensed to commercial third parties and his work has been published in
several book chapters and in about 200 papers in
international scientific journals of high impact (~ 3500
citations). He is on the editorial board of the journals ‘Antiviral Research’ and ‘Antiviral Chemistry and
Chemotherapy’, ad hoc reviewer for about 30 scientific
journals, member of several national and international
scientific committees and on the Board of Directors
of the International Society for Antiviral Research. He
is the CSO and co-founder of the KULeuven spin-out
company Okapi Sciences NV. He has given close to
100 invited lectures. He is teaching medical virology at
the school of dentistry and the school of medicine at
the KULeuven. He has been honored with a number of
awards including the Dr. Schamelhout-Koettlitz prize
from the Royal Belgian Academy of Medicine, the
Princess Josephine Charlotte prize from the Belgian
Fund for Scientific Research and the William Prusoff
Lecture Award from the International Society for
Antiviral Research. The Neyts lab has been partners
in four EU FP6 funded consortia, i.e. a “Network of
Excellence”, VIRGIL [www.virgil-net.org] on antiviral
drug resistance, the “Integrated Project” VIZIER [www.
viziereurope.org] on the replication machinery of RNA
viruses as targets to inhibit viral replication, a “specific
targeted project” “Dengframe” [www.denframe.org]
to identify strategies to control dengue and the “Coordinated Action” RiviGene [www15.bni-hamburg.de/
bni/others/rivigene] on highly pathogenic viruses. He
is the coordinator of a large NIAID/NIH funded project
on poxvirus inhibitors and of a major project, funded
by the Wellcome Trust, on Dengue drug discovery.
Sunday Omilabu
He’s head of the Virology Research
Unit, Department of Medical Microbiology and Parasitology, College of
Medicine, University of Lagos, Nigeria.
He is the current Dean, School of Basic
Medical Sciences, CMUL. His academic and professional Qualification. Include a BSc (Hons) Ife, MSc,
and a PhD (Ibadan). Dr. Omilabu’s main research
topics include: Identification and characterization of
viruses circulating in Nigeria; epidemiology of some
viruses of medical/zoonotic importance in Nigeria;
potency and efficacy of live viral vaccines used in
Nigeria; antiviral activities of tropical medicinal plants;
and molecular diagnosis of viruses of public health
importance in Nigeria. In collaboration with a group
in Luxembourg, wild Measles virus strains circulating
in Lagos were characterized using molecular biology
techniques. Together with a group in Stuttgart,
Germany, rotavirus isolated from diarrhoeic children
in Lagos was identified and genetically characterized.
The first Nigerian strain of rotavirus was successfully
adapted to tissue culture and activity of Rotavirus,
Adenovirus, and Astrovirus in diarrhoeic children in
Ilorin, Nigeria, was investigated. Currently, S.A. Omilabu’s laboratory collaborates with a group in Germany
on the molecular typing of Lassa fever virus circulating in Nigeria. In a series of collaborative studies
with the departments of Paediatrics and Surgery of
the College of Medicine, University of Lagos, viruses
causing acute respiratory tract infection in children in
Lagos were isolated and identified for the first time.
S.A. Omilabu’s contributions on viral epidemiology in
Nigeria include distribution and ecology of important
viruses causing human diseases in Nigeria, including
Potiskum virus, Igbo-Ora virus, Influenza virus, Yellow
fever virus, West Nile virus, Wesselsbron virus, Cytomegalovirus, African Horse Sickness virus, Human
Immunodeficiency virus and Lassa fever virus.
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
- 19 -
Ramesh S. Paranjape
Ramesh S. Paranjape is the Director
of the National AIDS Research Institute
at the Indian Council of Medical
Research, Pune. He has a BSc in
Zoology from Fergusson College
(1972), an MSc in Medical Microbiology from All
India Institute of Medical (1975) and a PhD in Medical
Microbiology (1982). Dr. Paranjape joined the services
of the Indian Council of Medical Research in 1976 at
Chennai. From 1976 to 1993 his area of work included
the immunology of Filariasis and Tuberculosis trying
to develop diagnostic assays and to understand the
responses of human body to these disease causing
organisms and the impact of the responses on the
disease manifestation. In 1993, Dr. Paranjape joined
the National AIDS Research Institute, Pune and the
focus of his research was shifted to HIV and AIDS,
primarily focused on understanding the immune
response to HIV. He currently heads the National
AIDS Research Institute, a permanent research institute of Indian Council of Medical Research. The Institute is carrying out programmes for development of
HIV vaccine indigenously. A first ever HIV vaccine trial
was launched under the leadership of Dr. Paranjape
at Pune. As a part of his research career Dr. Paranjape
has visited a number of countries, has received training in advanced technologies in prestigious Institutes
such as National Institutes of Health, USA and Johns
Hopkins University, Baltimore, USA. He has over 100
research publications in national and international
scientific journals. He has written popular science articles including a book in HIV and AIDS in Marathi. He
is also recognized as guide for PhD studies by Madras
and Pune University.
Bruno Spire
Social researcher in Marseille, France.
Born in 1960, he got his MD degree in
1985. He obtained his PhD in virology in
1990. In the early 1980’s he worked
in the laboratory at the Institut Pasteur
with Françoise Barré-Sinoussi and participated in the
first studies aimed at characterizing HIV. In the 1990’s
he worked in HIV molecular virology on the role of the
/vif/ accessory gene. In 1999, he switched to social
sciences and public health issues and focused his
work on adherence to antiretroviral treatment, quality
of life and risky behaviours of people living with HIV/
AIDS. He has a permanent position in the French
National Research Institute for Medical Research
and leads his own group in the field of public health
applied to HIV. Dr. Spire is openly HIV-positive and is
the President of the French community-based NGO
AIDES.
- 20 -
Brahm S. Srivastava
Emeritus Scientist at Central Drug
Research Institute, Lucknow. He has
served as Deputy Director and Head
of Microbiology at Central Drug
Research Institute and Professor and
Chairman of Biotechnology at Jawaharlal Nehru
University, New Delhi. Dr Srivastava graduated from
Banaras Hindu University with a PhD degree and did
Post-doctoral research in Belgium and the USA. He
works on virulence factors, pathogenesis, vaccine
and diagnosis of Vibrio cholerae and Mycobacterium
tuberculosis. He has been elected a Fellow of The
National Academy of Sciences, India and American
Academy of Microbiology. He has received prestigious awards from CSIR, ICMR, and INSA.
Jonathan Stoye
Head of the Division of Virology at the
Medical Research Council’s National
Institute for Medical Research in Mill Hill,
London. He received his BA degree
from the University of Cambridge,
UK; his PhD from Basel University, Switzerland; and
postdoctoral training in the laboratory of John Coffin at
Tufts University School of Medicine in Boston, Massachusetts, USA. His scientific career has been devoted
to understanding the mutual relationship between
retroviruses and their hosts with particular emphasis
on endogenous retroviruses and host factors such as
Fv1 and TRIM5 that limit retrovirus replication.
Jan ter Meulen
Executive Director of Vaccine Basic
Research at the Merck Research
Laboratories, West Point, PA. He is
responsible for the leadership of the
department, overseeing all laboratory
research on vaccines in the field of infectious diseases,
ranging from the identification of protective antigens
to testing vaccine candidates in non-human primates.
He holds an adjunct professorship of virology at the
University of Marburg, Germany, is a board certified
medical microbiologist, holds a diploma in tropical
medicine (London), and is a member of the College
of Physicians of Philadelphia. Prior to joining Merck
& Co. in 2008, he worked for five years at Crucell
Holland bv on the discovery and development of
novel vaccines and human monoclonal antibodies
against multiple infectious diseases targets, e.g.
Ebola, SARS, West Nile, H5N1 influenza, grampositive bacteria and P. falciparum. Dr. ter Meulen pursued
his academic career with a focus on tropical viruses
at the German Center for Cancer Research, Heidelberg, the Bernhard Nocht Institute for Tropical Medicine, Hamburg, and the Philipps University, Marburg.
From 2000-2005 he was an International Scholar of
the Howard Hughes Medical Institute in the Infectious
Diseases and Parasitology program, through which
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
he received support for his field studies on Lassa fever
in West Africa. He has over 60 peer-reviewed publications, is an associate editor of the Journal of Clinical
Virology, and served as a consultant and reviewer to
the German Ministry of Science and Education, the
Scientific Directorate of the European Community, the
International Science and Technology Center, Moscow
(ISTC), and the NIH.
Noel Tordo
Directeur de la Recherche Technologique au CEA, Directeur du CEA
Grenoble. His role is “Chef de Laboratoire” at the Pasteur Institute, Department of Virology. Dr. Tordo graduated
from the DEA - Molecular and Cellular Biology (1981),
Strasbourg and completed his PhD in MicrobiologyVirology in 1988, Paris VII HDR (1993). Dr. Tordo is
the Director of the Course of Fundamental Virology,
Pasteur Institute; Organisation of Theoretical & Practical Virology Courses in France, in Europe (Portugal,
Bulgaria, Finland, Sweden) and elsewhere (Brasil,
Hong-Kong, Algeria, Morocco); Organisation of
Congress, Seminars, Workshops (France, Belgium,
Turkey, Portugal, Algeria, South-Africa, Brasil, Mexico,
USA); Redaction, Editorial Board, Societies :J. Gen.
Virol., Microbes & Infection, Annales IP, Iranian Med.
J., Virologie
Member of the French Society for Microbiologie,
AAEIP, European Society for Vet. Virol., Basilian
Society for Virology; and the Director of the Course
of Fundamental Virology, Pasteur Institute. His other
responsibilities include:
-ICTV: Head of the Rhabdovirus Study Group
-WHO-PAHO-private companies: Expert, Consultant
-INRA: Scientific Council Animal Health (member)
-AFSSA: Scientific Council Animal Health (member)
-International Consortium for Antivirals (co-founder)
-Scientific commitees (Pole génomique de Shanghai)
-Expert for Scientific Journals (reviewer),
-Scientific Insitutes (INRA, IRD, CNEVA, CIRAD)
-Director of the Course of Fundamental Virology,
Pasteur Institute
Dr. Tordo has received the Académie Nationale de
Médecine (1987); the Académie des Sciences (1988)
and the Chevalier des Palmes Académiques (2006)
Queensland which presented attractive and relevant
research opportunities. Dr. Vasudevan rose through
the ranks (Senior Lecture (1997), Reader (2000)) and
in January 2003 made a career detour to become the
Head on Dengue Research at the newly established
Novartis Institute for Tropical Diseases (NITD) that
has as its core, the mission to discover anti-Dengue
drugs for therapeutic and possibly preventative use.
He played a significant role in advancing this course
by building a world-class dengue research department and developing a strong pipeline of projects. Dr.
Vasudevan was also one of the key drivers in establishing NEHCRI, a collaboration between two major
Indonesian Institutions and NITD with laboratories in
Makassar and Jakarta. In March 2008 he joined the
Duke-NUS Graduate Medical School where he is an
Associate Professor and Principal Investigator in the
Program in Emerging Infectious Diseases.
Anna Vyakarnam
She gained a 1st Class BSc Hons in
Microbiology from the University of
Poona, India, after which she studied
for an MSc in Applied Immunology at
Brunel University. She then studied
for her PhD at Cambridge University, after which she
worked as a Post doctoral researcher at the University of Cambridge. She then joined University College
London, as an Honorary Lecturer.She is currently
a Senior Lecturer in Infectious Diseases at King’s
College London. One objective of her group is to
identify and characterise host cell factors that regulate
HIV infection. The strategy is based on the knowledge
that human CD4 T-cells of the same genetic origin can
differ substantially in their susceptibility to HIV infection, despite expression of the critical HIV receptor /
co-receptors. The second objective of Dr.Vyakarnam’s
group is translational research in elucidating the antiviral and immune regulatory properties of CD4 T-cells
from patients who do exceptionally well clinically
following HIV infection (so called long-term non-progressors {LTNP}) or following multiple exposures to
HIV (so called highly-exposed persistently seronegative individuals {HEPS}).
Subhash Vasudevan
He obtained his BSc Hon (1985) from
LaTrobe University and his PhD (1989)
in Biochemistry from the Australian
National University. His first postdoctoral fellowship was completed at the
Max Planck Institute for Biophysics (1989-1991) and
after spending another year in the at the Research
School of Chemistry at the Australian National University he was appointed as a Lecturer in the Biochemistry
and Molecular Biology Department at James Cook
University (Jan 1993) in Australia. The first year of his
position coincided with a dengue outbreak in North
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
- 21 -
Dana Wolf
Senior Physician in Infectious Diseases,
and the Director of the Clinical Virology
Unit and the Clinical Virology Laboratory at the Hadassah University Medical
Center, Jerusalem, Israel. Her areas
of interest include: The epidemiology and impact of
known and newly discovered respiratory viruses as
revealed over a prospective 5-year study in young
children; Human cytomegalovirus replication mechanisms and novel antiviral drug targets - including
the antiviral activities of new UL97 kinase inhibitors,
and the anti-malarial artemisinin derivatives; Human
cytomegalovirus antiviral drug resistance; Congenital
cytomegalovirus infection: determinants of transmission and disease; and the role of viral immune evasion
mechanisms. Prof. Wolf is a member of the Israeli
Ministry of Health Advisory Committee on Immunization Practices and Infectious Diseases, the National
Pandemic Preparedness Team, and the European
Congenital CMV Initiative.
NOTEPAD
Paul Young
He completed his Honours degree at
QIMR in 1976. He then moved to the
UK where he completed his PhD studies
on the arenaviruses at the London
School of Hygiene & Tropical Medicine.
He became a member of academic staff and began his
dengue research program in 1986, initially in the area
of vaccine development. After 11 years at LSHTM he
returned to Australia in 1989 to SASVRC, Royal Children’s Hospital with a UQ joint appointment as Senior
Lecturer. He transferred to a full-time appointment
at UQ in 2000. His current interests are in the molecular virology, diagnosis and control of dengue and
West Nile viruses as well as respiratory syncytial virus.
His group is also studying the engagement currently
being enacted in the wild between a novel retrovirus
and its host, the koala, and what this can tell us about
cancer induction and viral evolution.
- 22 -
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
- 23 -
- 24 -
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
- 25 -
- 26 -
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France
- 27 -
- 28 -
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY
October 3rd - 6th, 2009 - Corsica, France